Efficacy and safety of DEB-TACE combined with HAIC and donafenib in the treatment of unresectable hepatocellular carcinoma: a dual-center retrospective study
Compared with DEB-TACE combined with donafenib, the combination of DEB-TACE, HAIC, and donafenib demonstrated superior tumor control and survival benefit in patients with uHCC, with an acceptable safety profile. Further prospective randomized controlled trials are warranted to validate the long-term efficacy and safety of this combination strategy.
Authors
- Qikun Guo
- Xuexian Zhang (ORCID: https://orcid.org/0000-0001-6014-926X)
- Si Shi (ORCID: https://orcid.org/0000-0002-6652-0629)
- Miao Chu (ORCID: https://orcid.org/0000-0002-6430-2089)
- Wei Luo (ORCID: https://orcid.org/0000-0002-4317-636X)
- Jian Long (ORCID: https://orcid.org/0000-0003-3631-2009)
- Xiaofeng Fang (ORCID: https://orcid.org/0000-0001-8961-3150)
- Ruidong Wang (ORCID: https://orcid.org/0009-0004-3217-7967)
- Bin Xiong (ORCID: https://orcid.org/0000-0003-3657-8405)
Institutions
- Kunming Medical University (CN)
- First People’s Hospital of Jingmen (CN)
- First Affiliated Hospital of Guangzhou Medical University (CN)
- Qujing Normal University (CN)
- First Affiliated Hospital of Kunming Medical University (CN)
- Guangzhou Medical University (CN)
Publication Details
- Journal
- BMC Cancer
- Published
- 2025-10-31
- DOI
- https://doi.org/10.1186/s12885-025-14879-2
- Primary Topic
- Hepatocellular Carcinoma Treatment and Prognosis
- Type
- article
- Field-Weighted Citation Impact
- 0.00